Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Evan Mulligan

Newcastle AuthorsTitleYearFull text
Dr Evan Mulligan
Dr Susan Tudhope
Dr Jill Hunter
Sarah Elliott
Dr Jonathan Wallis
et al.		Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling2023
Dr Elaine Willmore
Dr Aaron Ions Gardner
Dr Susan Tudhope
Belinda Murtani
Jessica Caffry
et al.		Novel small molecule IKK alpha inhibitors inhibit non- canonical NF-kappa B signaling and survival of primary CLL cells2015
Dr Ashleigh Herriott
Dr Susan Tudhope
Gesa Junge
Natalie Rodrigues
Dr Miranda Morton
et al.		PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in Chronic Lymphocytic Leukaemia2015
Dr Asima Mukhopadhyay
Michelle Dixon
Dr Evan Mulligan
James Murray
Professor Nicola Curtin
et al.		Evaluation of different methods to assess homologous recombination status and sensitivity to parp inhibitors in ovarian cancer2014
Professor Ruth Plummer
Dr Evan Mulligan
Professor Nicola Curtin
Professor Hilary Calvert
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation2013
Dr Susan Tudhope
Dr Evan Mulligan
Dr Jill Hunter
Dr Helen Marr
Emeritus Professor Barbara Durkacz
et al.		P B S-1086, a "Pan-Rel" Inhibitor, Decreases Viability of Chronic Lymphocytic Leukemia Cells2012
Dr Sarah Johnson
Clark Crawford
Dr Evan Mulligan
Dr Jonathan Wallis
Dr Tryfonia Mainou-Fowler
et al.		Mitoxantrone in combination with an inhibitor of DNA-dependent kinase: a potential therapy for high risk B-cell chronic lymphocytic leukaemia2011
Dr Yvette Drew
Dr Evan Mulligan
Wan Vong
Huw Thomas
Suzanne Kyle
et al.		Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA22011
Huw Thomas
Suzanne Kyle
Rafal Zur
Dr Evan Mulligan
Professor Nicola Curtin
6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance2010
Dr Elaine Willmore
Dr Evan Mulligan
Dr Sarah Elliott
Emeritus Professor Barbara Durkacz
ATM Mutant Chronic Lymphocytic Leukaemia Cells are Chemosensitized by Inhibition of DNA Dependent Protein Kinase2010
Rachel Daniel
Dr Agata Rozanska
Dr Evan Mulligan
Dr Yvette Drew
Huw Thomas
et al.		Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-0146992010
Dr Evan Mulligan
Dr Natalie Ferry
Professor Angharad MR Gatehouse
Characterisation of adult green lacewing (Chrysoperla carnea) digestive physiology: impact of a cysteine protease inhibito and a synthetic pyrethroid2010
Dr Evan Mulligan
Arabella Baird
Dr Jonathan Wallis
Dr Stephany Veuger
Emeritus Professor Barbara Durkacz
et al.		Relationships Between Aberrant Activity of the NF-kappa B Subunits and Outcome In Chronic Lymphocytic Leukemia: The Dual Role of DNA Damage Sensor Enzymes2010
Dr Agata Rozanska
Dr Evan Mulligan
Huw Thomas
Deborah Castelbuono
Professor Deborah Tweddle
et al.		[abstract] Central nervous system (CNS) penetration, poly-ADP ribose polymerase (PARP) inhibition and enhancement of temozolomide activity against childhood medulloblastoma by AG-0146992009
Dr Evan Mulligan
Tomasz Zaremba
Dr Yvette Drew
Professor Ruth Plummer
Professor Nicola Curtin
[abstract] Validated sensitive immunological determination of PARP-1 protein levels and activity in cultured cells and human lymphocytes2009
12